These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7981318)

  • 1. An enzymatic assay for the MAO-B inhibitor selegiline in plasma.
    Mahmood I; Neau SH; Mason WD
    J Pharm Biomed Anal; 1994 Jul; 12(7):895-9. PubMed ID: 7981318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry.
    Slawson MH; Taccogno JL; Foltz RL; Moody DE
    J Anal Toxicol; 2002 Oct; 26(7):430-7. PubMed ID: 12422997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An improved fluorimetric assay for brain monoamine oxidase.
    Morinan A; Garratt HM
    J Pharmacol Methods; 1985 Jun; 13(3):213-23. PubMed ID: 3923270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
    Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
    Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal selegiline: targeted effects on monoamine oxidases in the brain.
    Wecker L; James S; Copeland N; Pacheco MA
    Biol Psychiatry; 2003 Nov; 54(10):1099-104. PubMed ID: 14625153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl.
    Robinson JB
    Biochem Pharmacol; 1985 Dec; 34(23):4105-8. PubMed ID: 3933519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl-deprenyl in pig plasma.
    Szebeni G; Lengyel J; Székács G; Magyar K; Gaál J; Szatmári I
    Acta Physiol Hung; 1995; 83(2):135-41. PubMed ID: 8588500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
    Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
    Youdim MB; Gross A; Finberg JP
    Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced cardiovascular effects of methamphetamine following treatment with selegiline.
    Schindler CW; Gilman JP; Graczyk Z; Wang G; Gee WL
    Drug Alcohol Depend; 2003 Nov; 72(2):133-9. PubMed ID: 14636968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.
    Lamensdorf I; Porat S; Simantov R; Finberg JP
    Br J Pharmacol; 1999 Feb; 126(4):997-1002. PubMed ID: 10193780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
    Abassi ZA; Binah O; Youdim MB
    Br J Pharmacol; 2004 Oct; 143(3):371-8. PubMed ID: 15339864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase B inhibitor, selegiline, reduces
    Ng KP; Pascoal TA; Mathotaarachchi S; Therriault J; Kang MS; Shin M; Guiot MC; Guo Q; Harada R; Comley RA; Massarweh G; Soucy JP; Okamura N; Gauthier S; Rosa-Neto P
    Alzheimers Res Ther; 2017 Mar; 9(1):25. PubMed ID: 28359327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.